First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
Clinical trial NCT03852511 · COMPLETED
Trial details
- NCT number
- NCT03852511
- Sponsor
- Akamis Bio
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-19
- Primary completion
- 2022-02-04
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.